Bivalent COVID-19 Vaccines for Children 6 Months and Older

December 14, 2022
www.illinoisvaccinates.com/

VACCINE IMPLEMENTATION
SUPPORT, EDUCATION, AND RESOURCES

The goal of I-VAC is to ensure Illinoisans are being immunized against COVID-19 at every opportunity and providers are prepared to immunize all eligible age-groups. Providers and provider organizations throughout Illinois are encouraged to participate in this free program. Participants will receive support in their own initiatives to expand COVID-19 vaccine administration into routine patient care workflows in primary care settings, hospital urgent care centers, and upon hospital discharge.
On Today’s Call

- Illinois Department of Public Health
- Chicago Department of Public Health
- Dr. Susan Sirota, MD, FAAP
  - Assistant Professor Clinical Pediatrics Northwestern University Feinberg School of Medicine, Chair, PediaTrust, LLC
Eligibility - Pfizer

A single third (primary) dose for children who have received only two doses of the Pfizer monovalent primary series.

- For children aged 6 months through 4 years.
- A third dose of bivalent vaccine can be used to complete a child’s primary series in this age group.
- Children who received three doses of monovalent Pfizer-BioNTech COVID-19 vaccine are not authorized to receive a bivalent COVID-19 vaccine at this time.
- CPT Codes: NDC 59267-0609-02; CVX 302
Eligibility - Pfizer

▷ The use of Pfizer-BioNTech’s COVID-19 monovalent vaccine is no longer authorized for the third primary dose in children 6 months through 4 years of age.

▷ Children 6 months through 4 years of age that are due for their third dose of PfizerBioNTech COVID-19 vaccine must be rescheduled until their provider is able to administer the Pfizer bivalent vaccine.

▷ Going forward, monovalent vaccines given as third doses in a primary series in this age group must be reported to VAERS.
Eligibility - Moderna

A single booster dose for children who have received two doses of a monovalent COVID-19 vaccine.

- For children aged 6 months through 5 years.
- Children will need to complete two doses of monovalent Moderna COVID-19 vaccine before receiving a bivalent booster.

Note: Children 5 years of age and older are also authorized to receive a Pfizer BioNTech bivalent booster.

- CPT Codes: NDC 80777-0283-99, CVX 230
Additional Guidance

- The minimum interval between the last COVID-19 and a bivalent vaccine is two months, as with all age groups.
- **Heterologous (mix-and-match) bivalent vaccines is not authorized***.
# Storage & Handling

**PFIZER-BIONTECH STORAGE & HANDLING INFORMATION**

<table>
<thead>
<tr>
<th>AGE INDICATIONS</th>
<th>Monovalent</th>
<th></th>
<th></th>
<th>Bivalent</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months through 4 years</td>
<td>5 years through 11 years</td>
<td>12 years and older</td>
<td>6 months through 4 years</td>
<td>5 years through 11 years</td>
<td>12 years and older</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FORMULATION</th>
<th>Primary Series</th>
<th>Primary Series</th>
<th>Primary Series</th>
<th>Single Bivalent Primary Dose</th>
<th>Single Bivalent Primary Dose</th>
<th>Single Bivalent Booster Dose</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>VIAL CAP COLOR/ LABEL WITH COLOR BORDER</th>
<th>Maroon/ Orange</th>
<th>Gray</th>
<th>Maroon/ Bivalent label</th>
<th>Orange/ Bivalent label</th>
<th>Gray/ Bivalent label</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PREPARATION</th>
<th>Dilute Before Use</th>
<th>Dilute Before Use</th>
<th>Dilute Before Use</th>
<th>Dilute Before Use</th>
<th>Do Not Dilute</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>AMOUNT OF DILUENT NEEDED PER VIAL</th>
<th>2.2 mL</th>
<th>1.3 mL</th>
<th>Do Not Dilute</th>
<th>2.2 mL</th>
<th>1.3 mL</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>DOSE VOLUME/DOSAGE</th>
<th>0.2 mL/3 mcg</th>
<th>0.2 mL/10 mcg</th>
<th>0.3 mL/30 mcg</th>
<th>0.2 mL/3 mcg</th>
<th>0.2 mL/10 mcg</th>
<th>0.3 mL/30 mcg</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>DOSES PER VIAL</th>
<th>10 primary (after dilution)</th>
<th>10 primary (after dilution)</th>
<th>6 primary</th>
<th>10 primary (after dilution)</th>
<th>10 booster (after dilution)</th>
<th>6 booster or 1 booster</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ULT FREEZER (-90°C TO -60°C)</th>
<th>18 months</th>
<th>18 months</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>FREEZER (-25°C TO -15°C)</th>
<th>DO NOT STORE</th>
<th>DO NOT STORE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>REFRIGERATOR (2°C TO 8°C)</th>
<th>10 weeks</th>
<th>10 weeks</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ROOM TEMPERATURE (6°C TO 25°C) including any thaw time</th>
<th>12 hours prior to first puncture</th>
<th>12 hours prior to first puncture</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>AFTER FIRST PUNCTURE (2°C TO 25°C)</th>
<th>Discard after 12 hours</th>
<th>Discard after 12 hours</th>
</tr>
</thead>
</table>

---

4. Diluent: Sterile, 0.9% Sodium Chloride Injection, USP. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

8. Regardless of storage condition, vaccines should not be used after 12 months from the date of manufacture printed on the vial and cartons.

[illinoisvaccinates.com](http://illinoisvaccinates.com)
Pfizer Packaging

6 months – 4 years monovalent primary series vial and the 6 months – 4 years bivalent booster vials are both maroon
Pfizer Packaging

5-11 monovalent primary series vial and the 5-11 bivalent booster vials are both orange
Pfizer Packaging

- 12+ monovalent primary series vial and the 12+ bivalent booster vials are both gray

Pfizer monovalent vaccine

Primary Series ONLY

Pfizer bivalent booster

Booster Dose ONLY
## Storage & Handling

### Moderna Storage & Handling Information

<table>
<thead>
<tr>
<th>Age Indications and Formulation</th>
<th>Monovalent</th>
<th>Bivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months through 3 years (Primary Series)</td>
<td>6 years through 11 years (Primary Series)</td>
<td>12 years and older (Primary Series)*</td>
</tr>
<tr>
<td><strong>Vial Cap Color</strong></td>
<td>Dark Blue</td>
<td>Dark Blue</td>
</tr>
<tr>
<td><strong>Vial Label Border Color</strong></td>
<td>Magenta</td>
<td>Purple</td>
</tr>
<tr>
<td><strong>Preparation</strong></td>
<td>Do Not Dilute</td>
<td>Do Not Dilute</td>
</tr>
<tr>
<td><strong>Dose Volume/Dose</strong></td>
<td>0.25 mL/25 mcg</td>
<td>0.5 mL/50 mcg</td>
</tr>
<tr>
<td><strong>Doses Per Vial</strong></td>
<td>10 primary doses</td>
<td>5 primary doses</td>
</tr>
<tr>
<td><strong>Ult Freezer (-40°C to -60°C)</strong></td>
<td>DO NOT STORE</td>
<td>DO NOT STORE</td>
</tr>
<tr>
<td>*<em>Freezer (-50°C to -15°C)</em></td>
<td>Until expiration</td>
<td>Until expiration</td>
</tr>
<tr>
<td><strong>Refrigerator (2°C to 8°C)</strong></td>
<td>30 days</td>
<td>30 days</td>
</tr>
<tr>
<td><strong>Room Temperature (8°C to 25°C) including any thaw time</strong></td>
<td>24 hours</td>
<td>24 hours</td>
</tr>
<tr>
<td>*<em>After First Puncture (2°C to 25°C)</em></td>
<td>Discard after 12 hours</td>
<td>Discard after 12 hours</td>
</tr>
</tbody>
</table>

* Regardless of storage conditions, vaccines should not be used after the expiration date.
* After a vial is punctured 20 times it should be discarded even if the 12-hour time limit has not been met.
* Although labels may state “booster doses only”, the blue cap, purple label border presentation is only for use as a primary dose in ages 6-11.

[illinoisvaccinates.com](http://illinoisvaccinates.com)
Thawing Instructions

▸ Moderna 6 months to 5 years bivalent
  ▸ Refrigerator (2°C - 8°C or 36°F - 46°F): Thaw for 45 minutes
  ▸ Room temperature (15°C - 25°C or 59°F - 77°F ): Thaw for 15 minutes
  ▸ After first puncture, discard vial after 8 hours
**Moderna Vials**

<table>
<thead>
<tr>
<th>Primary Series</th>
<th>Primary Series</th>
<th>Primary Series</th>
<th>Bivalent Booster</th>
<th>Bivalent Booster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages 6 months – 5 years</td>
<td>Ages 6 – 11 years*</td>
<td>Ages 12+</td>
<td>Ages 6 months – 5 years</td>
<td>Ages 6+ years</td>
</tr>
</tbody>
</table>

*Moderna product with a dark blue cap and purple border is labelled ‘For Booster Dose Only’ but is authorized for use of a primary series in children aged 6-11 years old. Please see the Dear HCP Letter for more information at [https://eua.modernatx.com/covid19vaccine-eua/providers](https://eua.modernatx.com/covid19vaccine-eua/providers).
PFIZER-BIONTECH COVID-19 VACCINATION SCHEDULE AND DOSING

Pfizer-BioNTech
Ages 6 months–4 years
Dose/injection volume (dose before use):
Primary Dose:
Pfizer Maroon Cap
Bivalent Booster:
Pfizer Maroon Cap

In 3-8 weeks
PRIMARY DOSE 1
30 μg/0.3 mL
In at least 2 months
PRIMARY DOSE 2
30 μg/0.3 mL
In at least 2 months
PRIMARY BIVALENT
60 μg/0.3 mL

Pfizer-BioNTech
5 year olds ONLY
Dose/injection volume (dose before use):
Primary Dose:
Pfizer Orange Cap
Bivalent Booster Options:
Pfizer Orange Cap

In 3-8 weeks
PRIMARY DOSE 1
10 μg/0.2 mL
In at least 2 months
PRIMARY DOSE 2
10 μg/0.2 mL
In at least 2 months
PRIMARY BIVALENT
10 μg/0.2 mL

Pfizer-BioNTech
Ages 6 years–11 years
Dose/injection volume (dose before use):
Primary Dose:
Pfizer Orange Cap
Bivalent Booster Options:
Pfizer Orange Cap
Moderna Dark Blue Cap (gray label)

In 3-8 weeks
PRIMARY DOSE 1
10 μg/0.2 mL
In at least 2 months
PRIMARY DOSE 2
10 μg/0.2 mL
In at least 2 months
BIVALENT
10 μg/0.2 mL

Pfizer-BioNTech
Ages 12 years and older
Dose/injection volume (dose before use):
Primary Dose:
Gray Cap
Bivalent Booster Options:
Pfizer Gray Cap
Moderna Dark Blue Cap (gray label)

In 3-8 weeks
PRIMARY DOSE 1
30 μg/0.3 mL
In at least 2 months
PRIMARY DOSE 2
30 μg/0.3 mL
In at least 2 months
BIVALENT
30 μg/0.3 mL

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.

1 Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

2 Some studies in adolescents and adults have shown the small size of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–15 years. Source: CDC.

See the Pfizer-BioNTech COVID-19 Vaccine Guidance for children who are transitioning from a younger to older age group during their vaccination window.

See the CDC’s Guidance for latest updates and information on who is considered moderately or severely immunocompromised.

Funding for this project was made possible by the Office of Disease Control, through the Illinois Department of Public Health.

illinoisvaccinates.com
PFIZER-BIONTECH COVID-19 VACCINATION SCHEDULE AND DOSING
FOR MODERATELY TO SEVERELY IMMUNOCOMPROMISED POPULATIONS

I-VAC
ILLINOIS VACCINATES AGAINST COVID-19
A project led by the Illinois Chapter of the American Academy of Pediatrics

See the Pfizer-Biontech COVID-19 Vaccine Guidance for children who are transitioning from a younger to older age group during their vaccination window.

* Complete the primary series with the same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years. Source: CDC.

See the CDC's Guidance for latest updates and information on who is considered moderately or severely immunocompromised.

Funding for this project was made possible by the Office of Disease Control through the Illinois Department of Public Health.

illinoisvaccinates.com
MODERNA COVID-19 VACCINATION SCHEDULE AND DOSING

**Modern**
- Ages 6 months – 4 years
  - Dose/injection volume: 10 μg/0.25 mL
  - Primary Dose:
    - Blue Cap (magenta label)
    - Bivalent Booster Options:
      - Moderna Dark Pink Cap (yellow label)

**Modern**
- Ages 5 years only
  - Dose/injection volume: 10 μg/0.25 mL
  - Primary Dose:
    - Blue Cap (magenta label)
  - Bivalent Booster Options:
    - Moderna Dark Pink Cap (yellow label)
    - Pfizer Orange Cap

**Modern**
- Ages 6 months – 1 years
  - Dose/injection volume: 50 μg/0.5 mL
  - Primary Dose:
    - Blue Cap (purple label)
    - Bivalent Booster Options:
      - Moderna Dark Blue Cap (gray label)
      - Pfizer Orange Cap

**Modern**
- Ages 12 years and older
  - Dose/injection volume: 100 μg/1.0 mL
  - Primary Dose:
    - Blue Cap (blue label)
  - Bivalent Booster Options:
    - Moderna Dark Blue Cap (gray label)
    - Pfizer Gray Cap

See the Pfizer-BioNTech COVID-19 Vaccine Guidance for children who are transitioning from a younger to older age group during their vaccination window.

- Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
- Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).
- Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months – 6 years, especially for males ages 12–39 years. Source: CDC.

See the CDC’s Guidance for latest updates and information on who is considered moderately or severely immunocompromised.

Funding for this project was made possible by the Office of Disease Control, through the Illinois Department of Public Health.

[illinoisvaccinates.com](illinoisvaccinates.com)
MODERNA COVID-19 VACCINATION SCHEDULE AND DOSING
FOR MODERATELY TO SEVERELY IMMUNOCOMPROMISED POPULATIONS

**Moderna**

- **Ages 6 months–4 years**
  - Dose: Injection volume (as WFI: blue bottle)
  - Primary Dose: Blue Cap (magenta label)
  - Bivalent Booster Options: Moderna Dark Pink Cap (yellow label)

- **5 years old ONLY**
  - Dose: Injection volume (as WFI: blue bottle)
  - Primary Dose: Blue Cap (magenta label)
  - Bivalent Booster Options: Moderna Dark Pink Cap (yellow label)

- **Moderna**

- **Ages 6 years–11 years**
  - Dose: Injection volume (as WFI: blue bottle)
  - Primary Dose: Blue Cap (magenta label)
  - Bivalent Booster Options: Moderna Dark Blue Cap (gray label)

- **Ages 12 years and older**
  - Dose: Injection volume (as WFI: blue bottle)
  - Primary Dose: Blue Cap (magenta label)
  - Bivalent Booster Options: Moderna Dark Blue Cap (gray label)

**Booster Bivalent**

- **In at least 2 months**

---

**MODERNAS COVID-19 VACCINATION SCHEDULE AND DOSING**

**FOR MODERATELY TO SEVERELY IMMUNOCOMPROMISED POPULATIONS**

**See the Pfizer-Biontech COVID-19 Vaccine Guidance**

*Complete the primary series with same product, if the vaccine product previously administered cannot be determined or is no longer available. Any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.

*Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

*Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–15 years. Source: CDC.

See the CDC’s Guidance for latest updates and information on who is considered moderately or severely immunocompromised.

Funding for this project was made possible by the Office of Disease Control, through the Illinois Department of Public Health.

illinoisvaccinates.com

---

**See the Pfizer-Biontech COVID-19 Vaccine Guidance**

*Children who are transitioning from a younger to older age group during their vaccination window.*
FAQs

Will patients be able to mix and match products?

▷ Mostly not for the newly authorized group.
▷ See CDC’s Special Situations for COVID-19 Vaccination of Children and Adolescents.
FAQs

Can I vaccinate someone with a mild illness?

Absolutely, yes.

Per the [11.7.22 surge webinar with Dr. Barnes and Dr. Tan](#)
FAQs

Can other vaccines be given with bivalent boosters?
▷ YES!
FAQs

Will bivalent vaccines replace monovalent vaccines (primary series)?

To be determined. See COCA slides from 12.13.22 on primary doses here.

COVID-19 Primary Series Vaccination Recommendations

- People ages 6 months and older are recommended to complete a primary series.

- Monovalent vaccines should be used for the primary series, with one EXCEPTION:
  - Children ages 6 months–4 years who received 2 doses of a monovalent Pfizer-BioNTech vaccine are authorized to receive a bivalent Pfizer-BioNTech vaccine as their third primary series dose.

https://www.cdc.gov/vaccines/COVID-19/clinical-considerations/interim-considerations-us.html
**Ordering Information**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Pfizer</th>
<th>Pfizer*</th>
<th>Pfizer*</th>
<th>Moderna*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bivalent vaccines 6 months to 11 years</strong></td>
<td>1 tray (100 doses)</td>
<td>3 trays (180 doses for multiple dose vials)</td>
<td>50 doses</td>
<td>5 trays (100 doses)</td>
</tr>
<tr>
<td><strong>Bivalent Booster 12+</strong></td>
<td>10 vials per tray</td>
<td>10 vials per tray</td>
<td>10 vials per tray</td>
<td>10 vials per tray</td>
</tr>
<tr>
<td><strong>Bivalent Booster 12+ Single Dose Vials</strong></td>
<td>100 doses</td>
<td>60 doses</td>
<td>-</td>
<td>20 doses</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Minimum order quantity</th>
<th>~1 week</th>
</tr>
</thead>
</table>

- New single dose vials for Pfizer 12+ bivalent
- New minimum order quantity for Pfizer 12+
- Ancillary kits will still come in quantities of 300

Ancillary supplies will be provided for bivalent products, including a variety of 1-inch and 1.5-inch needles and syringes.

*Opt-out is available for pediatric products that do not require diluent.
Ancillary Kits

- Bivalent Moderna COVID-19 vaccines will come with 2 ancillary kits per minimum dose order will be sent to accommodate double the number of doses provided in each vial.
- Specify pediatric intent within vaccine orders to receive the appropriate ancillary kit.
- An ancillary opt-out continues to be available for all non-diluent kits.

Chicago sites: To opt out of ancillary supply kits, please email COVID19vaccine@cityofchicago.org
HOLIDAY SHIPPING HOURS

Vaccine shipping will pause for the holidays starting in mid-December 2022.

ORDERS BEFORE DECEMBER 9, 2022

- Orders approved by Friday, December 9th will ship before the holiday pause.
- Any orders that are submitted without updated/correct inventories, incomplete temperature logs, or other errors may not be able to be approved and may delay shipments.

ORDERS AFTER DECEMBER 9, 2022

- Orders submitted after December 9th will still be processed and may ship before the holiday shipping pause.
- Orders that do not ship will be sent starting on January 3rd, 2023.
HOLIDAY SHIPPING HOURS

PFIZER
• Orders placed in I-CARE and approved by Wednesday, December 14th at noon are expected to be delivered by December 22nd.
• No vaccine will be delivered between December 23, 2022 and January 2, 2023.

MCKESSON (MODERNA, NOVAVAX AND JANSSEN)
• Orders placed in I-CARE and approved by Wednesday, December 14th at noon are expected to be delivered by December 21st.
• No vaccine will be delivered between December 22, 2022 and January 3, 2023.

2023
• See above.
Additional Information

Provider facilities that do not require minimum order quantities should contact their local health department or other typical sources for vaccine redistribution, such as the State Vaccine Reallocation Tool.

Providers are asked to report their inventory to Vaccines.gov as soon as possible – include ages.
Reminders

▷ Some wastage is expected in order to vaccinate all eligible Illinoisians.

▷ Providers will NOT be penalized for wasting the remainder of a vial if they are only able to utilize a portion of the doses in the vial.
Upcoming Trainings and Support

I-VAC Office Hours
- Each one hour
- Follow [this link](#) to join on Zoom
Upcoming Webinars

- Illinois Vaccinates Against COVID-19 (I-VAC) Learning Collaboratives – Adult Populations
  - Register [here](#)
  - December 14th, 5:30pm, CME available – 2023 Learning Collaborative dates added

- I-VAC Vaccine Bootcamp (virtual) – This Friday!
  - December 16th, 8:00am – 12:15pm
  - Register [here](#)

- Illinois Vaccinates Against COVID-19 (I-VAC) Vaccine Bootcamp (in person)
  - U of I Hotel and Conference Center (1900 S 1st St, Champaign, IL 61820)
  - Target Audience: Physicians, PAs, Advanced Practice Nurses, RNs, Pharmacists, MAs, Vaccine Administrators. Register [here](#)
  - January 20th, 8:30am – 2pm
I-VAC Scheduling and Dosing Chart Links

- Pfizer:
  - Non-Immunocompromised
  - Moderately to Severely Immunocompromised
- Moderna:
  - Non-Immunocompromised
  - Moderately to Severely Immunocompromised
- Other COVID-19 Vaccines
Additional Resources

- 12.13.22 COCA Call Slides
- Interim Clinical Considerations for Use of COVID-19 Vaccines
- Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates
- FAQs for the Interim Clinical Considerations for COVID-19 Vaccination
- Pfizer-BioNTech COVID-19 Vaccines | FDA
- Moderna COVID-19 Vaccines | FDA
- Age transitions chart from CDC

Standing orders
- COVID-19 Moderna vaccine - 6 months through 5 years of age (dark blue vial cap with magenta [pink] bordered label)
- COVID-19 Moderna vaccine - 6 years through 11 years of age (dark blue vial cap with purple bordered label)
- COVID-19 Moderna vaccine - adults (12 years of age and older)
- COVID-19 Novavax vaccine - adults (12 years of age and older)
- COVID-19 Pfizer-BioNTech - 6 months through 4 years of age (maroon vial cap)
- COVID-19 Pfizer-BioNTech - 5 through 11 years of age (orange cap)
- COVID-19 Pfizer-BioNTech - 12 years and older (gray cap)
- Illinois Vaccinates Against COVID-19 (I-VAC)
  - Pediatric COVID-19 Vaccines FAQs – English, Spanish
  - Pediatric Boosters FAQs – English, Spanish
  - Updated Boosters FAQs – English, Spanish
  - FAQs on bivalent vaccines
- AAP dosing guide here
- Pfizer trainings here
- Moderna
  - Trainings link
  - Office hours and regional contacts link
Booster Recommendations

- Ages 6 months–4 years and completed the Moderna primary series: 1 bivalent Moderna booster dose.
- Ages 6 months–4 years and completed Pfizer-BioNTech primary series: No booster dose is recommended at this time.
- Age 5 years and completed Moderna primary series: 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech)
- Age 5 years and completed Pfizer-BioNTech primary series: 1 bivalent Pfizer-BioNTech booster dose.
- Ages 6 years and older and any primary series: 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech)
Contact Information

IDPH
- To enroll in I-CARE: dph.immunizations@illinois.gov
- For questions about vaccine orders: dph.vaccines@illinois.gov

CDPH
- Kevin Hansen: Kevin.Hansen@cityofchicago.org
- COVID19vaccine@cityofchicago.org
- Provider resources: https://www.chicagohan.org/covid-19-vaccine/provider

ICAAP/I-VAC
- Illinois Vaccinates Against COVID-19
- Stephanie Atella: satella@illinoisaap.com
- Facts@ilvaccinates.com

Pfizer
- Customer Service: Call 1-800-879-3477
- General Product Inquiries: Call 1-877-829-2619
- Pfizer Medical Information: Call 1-800-438-1985 or Visit PfizerMedicalInformation.com
- Controlant Customer Support: 1-701-540-4039
- Pfizer US Shipment Support: Call 1-800-666-7248

Moderna
- Customer Service: Call 1-866-MODERNA (1-866-663-3762) or Email ModernaPV@modernatx.com
- Chatbot here
Thank You

Happy holidays
FROM ICAAP